Abstract
Hepatocellular carcinoma (HCC), a malignancy of the liver, has become the second most lethal cause of cancer death globally. Recently, scientists discovered that a splenic erythroblast-like cell induced by the primary tumor, termed Ter-cell, promoted HCC progression and metastasis. These findings shed light on the inhibition of Ter-cell or artemin that can serve as a new therapeutic target for HCC.
Keywords:
antitumor agents; artemin; cancer; hepatocellular carcinoma; therapeutic targets.
© 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology*
-
Antineoplastic Agents / therapeutic use
-
Carcinoma, Hepatocellular / drug therapy*
-
Carcinoma, Hepatocellular / metabolism
-
Carcinoma, Hepatocellular / pathology
-
Disease Progression
-
Drug Discovery
-
Erythroblasts / drug effects*
-
Erythroblasts / metabolism
-
Erythroblasts / pathology
-
Humans
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / metabolism
-
Liver Neoplasms / pathology
-
Molecular Targeted Therapy
-
Neoplasm Metastasis / pathology
-
Neoplasm Metastasis / prevention & control
-
Nerve Tissue Proteins / antagonists & inhibitors*
-
Nerve Tissue Proteins / metabolism
Substances
-
ARTN protein, human
-
Antineoplastic Agents
-
Nerve Tissue Proteins